Enforcement Report - Week of November 17, 2021
Health Canada Recalls Marcan Pharmaceuticals` MAR-Cetrizine
Health Canada Recalls JAMP Pharma Corporations` JAMP-Cetrizine
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full advance payment of the future development and regulatory milestones for the product. Amendments were made to certain rights under non-financial clauses of the agreement.
Nicox SA announced that its partner, Ocumension Therapeutics, has initiated a phase 3 clinical trial in China with Zerviate, the first and only topical ocular formulation of the antihistamine cetirizine, for the treatment of ocular itching associated with allergic conjunctivitis.
The FDA on Wednesday said it is requiring a boxed warning and medication guide for Merck’s asthma and allergy drug Singulair (montelukast) and its generics to strengthen existing warnings about the risk of neuropsychiatric events, including suicides, linked to the drug.
The US Food and Drug Administration (FDA) on Wednesday said it is requiring a boxed warning and medication guide for Merck’s asthma and allergy drug Singulair (montelukast) and its generics to strengthen existing warnings about the risk of neuropsychiatric events, including suicides, linked to the drug.
French firm Nicox SA, an international ophthalmology company, has announced the signature of an exclusive license agreement with Samil Pharmaceutical Co., Ltd for the development and commercialization of ZERVIATETM (cetirizine ophthalmic solution), 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in South Korea.
How much are lawsuits hurting Johnson & Johnson's brand? The New Jersey drugmaker has lost half a billion dollars in brand value over the past year, according to Interbrand’s Best Global Brands for 2019 ranking, out Thursday. The company dropped in the brand consultancy’s tally to No. 86 with $5.72 billion in brand value, down 8% from last year’s finish at No. 77 with $6.23 billion.